Lambert-Eaton Myasthenic Syndrome: 3,4-DAP Against a Remote Seizure History
A new small-cell-lung-cancer-associated LEMS diagnosis with worsening bulbar symptoms runs straight into amifampridine's labeled seizure contraindication — built on a single, self-limited seizure from fifty-seven years ago that nobody has had reason to revisit since.
W.N., 66, spent thirty years as a freight dispatcher and now spends most evenings in his garage workshop as an amateur radio operator, logging contacts with operators as far away as New Zealand in a running log he has kept for over a decade. Over the past two months he has grown noticeably weaker rising from chairs and climbing the stairs to his workshop, developed drooping eyelids and a persistently dry mouth, and lost twelve pounds without trying. In the last two weeks several of the operators he checks in with most nights have started asking if he has caught a cold, and he has begun favoring soup over solid food himself, without needing anyone to point it out. He quit smoking twenty years ago after a two-pack-a-day habit going back to his twenties — the real reason a chest CT was ordered once the weight loss and weakness stopped looking like ordinary aging, and the reason it found what it found: a 3.2cm left hilar mass, biopsy-confirmed small-cell lung cancer, limited stage. Repetitive nerve stimulation showed a decremental response at low rates and a markedly incremental response, more than doubling, at high rates and after brief exercise — the characteristic electrophysiologic signature of this disease. Voltage-gated calcium channel antibody came back positive.
One detail complicates what should otherwise be a straightforward decision to start amifampridine alongside his chemotherapy, which current guidance treats as the standard, concurrent approach in SCLC-associated LEMS: at age nine, fifty-seven years ago, he had a single generalized seizure after a bicycle accident, documented in old family records as “seizure disorder, resolved,” and never repeated, on or off medication, since. Amifampridine’s FDA label is unambiguous on its face — contraindicated in patients with a history of seizures — and does not specify how remote that history needs to be before it stops describing the same risk. Meanwhile his bulbar symptoms are worsening on a clock that has nothing to do with how that question eventually gets answered.
New diagnosis, deciding what starts today
The FDA label for amifampridine doesn’t hedge on this: contraindicated in patients with a history of seizures, full stop, and it’s worth taking that at face value rather than arguing our way around it. LEMS is also one of the few paraneoplastic syndromes known to respond directly to tumor-directed therapy — get the chemotherapy started, and there’s a real chance a meaningful share of his weakness improves without needing a drug the label tells us not to use.
You’re right that the label doesn’t hedge on the word ‘seizures’ — but it also doesn’t define how remote a history has to be before it stops describing the same risk.
“Take it at face value” is doing more work than it looks like: the two-percent seizure incidence the label is built on came from patients on the drug at recommended doses, many of them already taking something else that lowered their seizure threshold — not from a cohort that includes a fifty-seven-year unremarkable interval like his. He’s having trouble swallowing solid food right now, tonight, and chemotherapy’s own response curve runs in weeks, not days; I don’t think we can just wait that out.
You’re both arguing about a drug he doesn’t need to start today to address what’s actually urgent. Pyridostigmine works through a completely different mechanism — it doesn’t touch the potassium channels amifampridine does, so none of tonight’s seizure question applies to it at all. It won’t get him back to where amifampridine might, but it’s real, it’s fast, and it buys us the one thing neither of your positions actually has yet: time to see what his first cycle of chemotherapy does on its own before anyone has to resolve the seizure-history question under pressure.
Agreed: pyridostigmine starts today as an immediate bridge for his bulbar symptoms, chemotherapy begins per the standard limited-stage protocol, and amifampridine is held — not ruled out — pending reassessment after the first cycle.
Not agreed: the medical oncologist and neurologist still disagree about whether his fifty-seven-year-old seizure history should be read as genuinely disqualifying if amifampridine turns out to be needed later, once chemotherapy’s own effect on his weakness becomes clearer. That question was explicitly left open rather than settled by today’s plan, which neither side treated as resolving it.